



Published in final edited form as:

Curr Res Cell Biol. 2020 ; 1: . doi:10.1016/j.crcbio.2020.100003.

Autophagy, Unfolded Protein Response and Lung Disease

Mohammad S. Akhter¹, Mohammad A. Uddin¹, Khadeja-Tul Kubra¹, Nektarios Barabutis^{*,1}

¹School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana 71201, USA

Abstract

Acute Respiratory Distress Syndrome is a severe disorder affecting thousands of individuals worldwide. The available medical countermeasures do not sufficiently suppress the unacceptable high mortality rates associated with those in need. Thus, intense efforts aim to delineate the function of the lung endothelium, so to deliver new therapeutic approaches against this disease. The present manuscript attempts to shed light on the interrelations between the unfolded protein response and autophagy towards lung disease, to deliver a new line of possible therapeutic approaches against the ferocious Acute Respiratory Distress Syndrome.

Keywords

Acute Lung Injury; COPD; Pulmonary Hypertension; Tuberculosis; Cystic Fibrosis; Endothelium

Autophagy in the UPR context

Autophagy is a well-orchestrated process, controlled by over 30 autophagy-related (ATG) genes [1]. It functions to remove the misfolded or aggregated proteins, to eliminate impaired organelles (i.e. mitochondria, peroxisomes), as well as to eradicate intracellular pathogens [2]. In addition, autophagy enhances cellular senescence, defends genome instability, and prevents necrosis [2].

Three different types of autophagy have been identified, namely the macro-autophagy, the micro-autophagy and the chaperone-mediated autophagy. Macro-autophagy is the most extensively studied type. Under normal physiological conditions, it helps to maintain the cellular homeostasis by degrading damaged or redundant organelles [3]. In stress conditions, including nutrient or energy deprivation, it degrades the cytoplasmic materials into metabolites to employ them towards biosynthesis, energy production, or cell survival [4].

*To whom correspondence should be addressed at: Nektarios Barabutis, M.Sc., Ph.D., School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, 1800 Bienville Drive, Monroe, Louisiana 71201, United States of America, barabutis@ulm.edu, Phone: (318) 342-1460, Fax: (318) 342-1737.

The authors declare that there are no conflicts of interest.

MSA drafted the paper, MAU and KTK edited the paper. NB revised the paper. All authors approve the content of the manuscript.

Publisher's Disclaimer: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Autophagy is primarily a cellular protective mechanism. However, excessive autophagy has been associated with various aspects of human pathology, including lung disease [5]. It can be measured by evaluating the levels of autophagic flux, by detecting the lipid modified form of the microtubule-associated protein 1A/1B-light chain 3 (LC3), as well as the autophagosome. Increased levels of autophagosomes do not always reflect enhanced autophagy, but it may represent blocked autophagosome fusion or degradation. Hence, the assessment of autophagic flux is important to accurately measure enhanced autophagy [6].

Autophagy enhances endogenous defense mechanisms by upregulating molecular chaperones [7], and it is regulated by the mammalian target of rapamycin (mTOR) [8]. Deactivation of mTOR enhances autophagy [9], which in turn regulates the unfolded protein response, a sensor of endoplasmic reticulum (ER) stress fluctuations. ER is a complex cellular organelle involved in protein synthesis and folding [10], as well as changes in Ca^{2+} concentrations [11].

The ER lumen contains an array of chaperones and enzymes for processing of nascent proteins. Thus, it provides a unique oxidizing environment to support the formation of disulfide bond during protein folding [12]. ER disruption due to hypoxia, nutrient deprivation, redox changes [13], increased secretory load, and increased load of mutated proteins [14] cause ER disturbance, accumulation of misfolded or unfolded proteins in the ER lumen and ER stress. Adapting to those conditions requires the activation of a highly conserved intracellular response mechanism, namely the unfolded protein response (UPR) [15].

The UPR is consisted of three transmembrane receptors. Those sensors are the protein kinase RNA like ER kinase (PERK), the activating transcription factor 6 (ATF6), and the inositol-requiring enzyme-1 (IRE1) [16]. Those receptors are bound to BiP [17]. The higher affinity of BiP to misfolded or unfolded proteins causes its dissociation from the previously mentioned UPR branches to trigger downstream signaling processes [18, 19].

Inactive PERK is monomeric. Upon BiP release, it homodimerizes and consequently trans-autophosphorylates. Activated PERK mediates the phosphorylation of the α -subunit of eukaryotic initiation factor 2 (eIF2); which in turn reduces the protein load in the ER [20]. ATF6 is a type II transmembrane receptor with two isoforms in the mammalian genome, namely the ATF6 α and ATF6 β . ATF6 α is involved in UPR gene expression [21]. After dissociation from BiP, ATF6 is transferred to the Golgi apparatus to be cleaved by site 1 protease (S1P) and site 2 protease (S2P). Those processes produce the active cytosolic p50 fragment, which migrates to the nucleus. That fragment activates the expression of genes which increase the ER folding capacity, and activate the endoplasmic reticulum-associated protein degradation pathway (ERAD) [21]. ATF6 activation has also been reported to regulate an array of miRNAs to ameliorate ER stress [22].

The type I ER transmembrane protein IRE1 accommodates two distinct domains in its cytoplasmic tail; a serine/threonine kinase domain and an endoribonuclease (RNase) domain [23]. IRE1 has two isoforms, namely the IRE1 α and IRE1 β . IRE1 α is predominantly expressed in almost all tissues. IRE1 β expression is limited only to the intestinal epithelial

cells [24] and the airway mucous cells [25]. IRE1, which is the most evolutionary conserved signaling branch of UPR [26]; it is closely associated with pro-survival pathways enabling the cells to adapt to stressful environments [27]. The release of IRE1 α from BIP causes its dimerization and auto-phosphorylation, which in turn activates IRE1 α [28]. It was also reported that IRE1 α binds directly to unfolded proteins, and becomes activated in a similar fashion [29].

The activated IRE1 α exerts RNase activity to cleave a single RNA encoding X-box binding protein 1 (XBP1). Those activities produce a potent transcriptional activator (XBP1s) [28]. XBP1s enters into the nucleus to induce the expression of several proteins that attenuate ER stress (i.e. ER-resident chaperone BiP, protein folding enzyme PDI, and translocation proteins) [30]. Furthermore, XBP1s augments the expression of the heat shock protein 40kda (DnaJ) and the ER-associated degradation system or ER-to-golgi transport components. Thus, it degrades unfolded proteins in the ER lumen [31, 32]. Recent observations suggests that Hsp90 inhibition induces the unfolded protein response in the lungs both *in vivo* and *in vitro* [33, 34], and that P53 might be involved in those effects [35–37].

A correlation between the unfolded protein response (UPR) and autophagy has been demonstrated in many studies. Several stimuli cause the accumulation of potentially toxic polypeptides in the ER lumen, and overload the capacity of the chaperone system. This condition eventually engenders ER stress, which triggers the activation of UPR to avoid cell damage and promote the protein folding capacity of ER [38]. Hence, it eliminates the impaired polypeptides through ERAD and ER stress-induced autophagy [39].

PERK activation and autophagy

The expression of autophagy-related proteins are significantly increased by the PERK-eIF2 α -ATF4 pathway [40, 41]. Phosphorylation of eIF2 α through ER stress-induced PERK activation causes the induction of ATF4. The latter protein binds to CHOP and consequently augments the transcription of various autophagy-related genes (e.g. Atg3, Atg7, and Atg12) [41].

The expanded polyglutamine 72 repeat (polyQ72) can induce autophagy through phosphorylation of PERK/eIF2 α [42]. PolyQ72 resides in the cytoplasm and inhibits the translocation and degradation of ER proteins through ERAD system. A combination of these two effects causes ER stress; which accelerates the Atg5-Atg12-Atg16 complex conversion, a process which involves LC3-I to LC3-II. LC3-II formation is an important characteristic of autophagy [42]. The chalcone Xanthoangelol promotes the UPR induced-autophagy via activation of the JNK/c-Jun pathway. It upregulates the expression of several proteins involved in autophagy (e.g LC3-II, Beclin-1, and Atg5 [43]. Oxidized lipids also employ the JNK-dependent autophagy by triggering UPR, and further promote cell survival during oxidative stress [44].

IRE1 α activation and autophagy

IRE1 initiates autophagy. Manganese (Mn) can induce IRE1 phosphorylation through UPR activation. Phosphorylated IRE1 is involved in JNK activation by producing the ASK1-TRAF2 complex [45]. JNK phosphorylates and activates c-Jun, upregulating Beclin 1 transcription [46]. Beclin1 exerts a crucial role in promoting autophagy through autophagosome formation. Hence, it serves as a molecular switch in the regulation of autophagy [47]. IRE1 induces autophagy via the IRE1-JNK pathway [48].

ATF6 activation and autophagy

Japanese encephalitis virus (JEV) induces autophagy in neuronal cells via ATF6 activation. The suppression of ATF6 by siRNA significantly decreased the levels of Atg3 and LC3-II [49]. The core protein of Hepatitis C virus promotes ATF6 activation and CHOP protein expression. The latter protein upregulates the transcription of LC3B by directly binding to its promoter region. Moreover, CHOP induces the expression of Atg5, promoting the autophagosome formation [50]. ATF6 activation is a pro-survival pathway for protecting the neuron after ischemic stroke, due to the elevation of autophagy in the neurons of ATF6-KI mice. The short-form of ATF6 (sATF6) upregulates LC3-II, downregulates p62, and activates mTOR in post ischemic brain [51].

Autophagy and UPR in chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Emphysema, inflammation, and fibrosis of the small airways have been associated with that disorder [52, 53]. Cigarette smoke (CS) is the most important risk factor of COPD [54]. The underlying molecular mechanism of COPD remains incompletely understood, and autophagy is considered a major mechanism which contributes to the pathogenesis of CS-induced COPD [55]. The lung tissues of COPD patients have been shown to express an elevated level of several autophagy markers; including LC3-II, Atg4, Atg5/12, and Atg7 as well as increased levels of autophagosomes [56]. Epithelial cell lining of alveoli and airways are the primary targets of inhaled CS. Autophagosome formation in the lung epithelial cells indicates the activation of autophagy pathway in COPD [57]. Aggrephagy [58] and mitophagy [59, 60] were observed in the epithelial cells of COPD patients. The activation of selective autophagy was associated with detrimental effects in lung epithelial cells.

Oxidative stress-induced growth inhibitor 1 (OSGIN1) is a link between CS-induced stress and elevated level of autophagy in the human airways epithelium [61]. OSGIN1 is an apoptotic regulator extensively upregulated in the smokers compared to the non-smokers. The increased expression of OSGIN1 causes apoptotic cell death through inducing the cytochrome C release from mitochondria [62]. CS induces the OSGIN1 expression in large and small airways epithelium, and this enhanced OSGIN1 upregulates autophagy through MAP1LC3B and SQSTM1 [61]. Moreover, suppression of the MAP1LC3B, PINK1, and Hdac6 protect from smoke-induced emphysema and impairment of mucociliary clearance [59, 63].

COPD is also linked to the particulate matter (PM) exposure. Chronic exposure to biomass fuel (BMF) and motor vehicle exhaust (MVE), which are the two major sources of PM emission, causes pulmonary inflammation, alveolar enlargement and airway remodeling [64]. Patients with pre-existing COPD are more susceptible to PM exposure than healthy individuals. Exposure to PM demonstrates a reduction in CCAAT/enhancer-binding protein alpha (C/EBP α) in human bronchial epithelial (HBE) cells. That triggers the anomalous expression of NADH dehydrogenase genes, and induces autophagy. Recuperation of lung damage by the autophagy inhibitor 3-MA; or the genetic suppression of Atg7 in PM-associated COPD dictates the deleterious effects of autophagy in COPD [65]. These studies suggest that autophagy in the lung epithelial cell lines contributes to the development of COPD.

Alveolar macrophages (AMs) are required for bacterial clearance from the alveolar surface and the prevention of the microbe-induced infection. The AMs of CS-induced COPD patients accumulate autophagosomes and p62. The reduced autophagy in AMs leads to impaired protein aggregate clearance, dysfunctional mitochondria, and defective delivery of bacteria to lysosomes (defective xenophagy). Those effects explain the recurrence of bacterial infection for smokers [66]. Furthermore, insufficient autophagy is also associated with the persistent inflammation in COPD. Leukotriene B4 (LTB4) produces inflammatory cytokines that makes a crucial contribution to chronic inflammation. In order to induce inflammatory pathway, LTB4 binds to its' highly specific LTB4 receptor 1 (BLT1) which is expressed primarily in leukocytes [67]. CS significantly increases the BLT1-positive AMs [68] that mediates inflammation through the LTB4/BLT1 pathway [69]. Inadequate autophagy of macrophages is linked to the LTB4-mediated inflammation in CS-induced COPD model. The BLT1 antagonist exerts anti-inflammatory activity by inducing autophagy in AMs, and was suggested to serve as a potential therapeutic approach for the COPD management.

The pathogenesis of CS-induced COPD is also associated with increased levels of reactive oxygen species (ROS) caused by CS-induced mitochondrial damage [60]. CS-induced mitophagy can be inhibited by the PTEN-induced kinase 1 (PINK1). Decreased levels of Parkin RBR E3 ubiquitin protein ligase (PARK2) expression has been observed in COPD lungs [60]. However, another study indicated that the PINK1-regulated mitophagy promotes necroptosis and cell death in lung epithelial cells, thereby contributing to COPD development [59]. PINK1 null mice were protected against mitochondrial dysfunction, airspace enlargement, and mucociliary clearance (MCC) during CS exposure. In humans, lung epithelial cells of COPD patients displayed increased levels of PINK1, suggesting that this pathway can be a therapeutic target for COPD [59].

Studies employing the mTOR inhibitor rapamycin demonstrated that although enhancing autophagy may be beneficial during CS-exposure, autophagy induction by rapamycin increases the number of apoptotic and inflammatory cells [70].

UPR is also associated with the pathogenesis of COPD. The process of protein folding and refolding produces reactive oxygen species (ROS) inside the ER lumen. Hence, a suitable redox environment is essential for the proper ER function. This redox environment is

maintained by different ER-resident enzymes; including the ER oxidoreductin-1 (Ero1) family [71]. Cigarette smoke induces ROS production, and affects protein oxidation in the ER lumen, at least in part by the protein disulfide isomerase (PDI) modulation [72]. Those events activate the UPR in normal human bronchial epithelial (NHBE) cells, mice lung epithelial 12 (MLE12) cells, alveolar type II cells and alveolar macrophages [72–74]. In addition, oxidative damage of different cellular proteins due to CS exposure compromises proteomic clearance, and results in the deposition of those aberrant proteins inside the cells [75].

The activation of UPR is rapid and cell type - dependent. Moreover, its effects depend on the duration of its induction. It was suggested that initial UPR induction is protective [73] while its chronic induction upregulates different pro-apoptotic protein including the CHOP and caspases [76–78]. Since production of ROS by CS is the underlying reason of UPR activation, scavengers of ROS demonstrate a promising effect in reducing UPR and consequently the CS-induced apoptosis in HBE cells [76]. Similarly, NHBE cells from COPD donors expressed increased level of the UPR markers, ATF4, XBP1 and CHOP. GPx-1 null mice shows increased expression of CS-induced markers and apoptosis [79]. CS can also upregulate the nuclear factor erythroid 2-related factor 2 (Nrf2). This protein heterodimerizes to induce genes involved in the protection of lung cells against oxidative stress. This phenomenon occur after the exposure of CS in human airway epithelial cells [73].

CS-induced UPR activation causes the impairment of efferocytosis. This is a process by which apoptotic cells are removed in the alveolar macrophages. CS suppresses the efferocytosis by activating RhoA in macrophages both *in vivo* and *in vitro* [80]. RhoA is a key element of the cytoskeletal integrity [81–83]. PERK mediates the suppression of efferocytosis and PERK inhibitors successfully reverse RhoA activity to restore efferocytosis in alveolar macrophages [84].

Interestingly, chaperone-mediated autophagy (CMA) exhibits a reduction of CS-induced UPR and the subsequent apoptosis. CMA is involved in the maintenance of homeostatic processes, and it is responsible for the selective degradation of proteins containing Lys-Phe-Gln-Arg-Gln (KFERQ) [85]. CS induces lysosome associated membrane protein 2A (LAMP2A) and CMA through Nrf2-dependent manner in HBE cells. Suppression of LAMP2A and CMA inhibition results in the enhancement of UPR and apoptosis. This effect can be reversed by the induction of the LAMP2A expression [86].

Autophagy and UPR in pulmonary hypertension (PH).

Pulmonary hypertension (PH) is a pathophysiological condition defined as an increase of mean pulmonary arterial pressure [87, 88]. The classification of PH was initially proposed in 1973, suggesting the primary and secondary PH. Later on a different set of categories were established to reflect more accurate pathophysiological mechanisms, hemodynamic characteristics and therapeutic approaches towards PH. The new clinical classification categorized PH in: 1) pulmonary arterial hypertension (PAH) 2) PH due to left heart disease 3) PH due to chronic lung disease and/or hypoxia 4) chronic thromboembolic PH 5) PH due

to unclear and/or multifactorial mechanisms. In the third, fourth and fifth international symposium held in 2003, 2008 and 2013 respectively, additional amendments have been adopted to improve the clarity and to include new information regarding the PH pathophysiology [89–91].

PAH is a fatal pulmonary disease that causes right ventricular failure and death. Although its etiology was previously unclear, scientists have made a significant progress in understanding the causes and development of PAH. PAH can be hereditary (HPAH), idiopathic (IPAH) or associated (APAH) with medical conditions associated to connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, and chronic hemolytic anemia. Furthermore, mutations in bone morphogenic protein receptor type 2 gene (BMPR2), activin-like kinase type 1 (ALK1) and endoglin (ENG) are associated with HPAH [92].

Hypoxia is a common cause of PH, associated with significant structural remodeling in the pulmonary arteries. The resident vascular cells (i.e. endothelial cells, smooth muscle cells, and adventitial fibroblasts) alter their proliferation, matrix protein production, cytokine release and receptor expression. Moreover, hypoxia potentiates the inflammation in the vasculature and recruits progenitor cells to advance structural vascular remodeling and vasoconstriction of the pulmonary circulation [93].

Elevated level of LC3B were observed in PH lungs [94]. LC3B knockout mice have shown increased susceptibility to hypoxia-induced PH. LC3B knockdown cells were associated to increased hypoxic cell proliferation. Those effects suggested adaptive functions of LC3B during hypoxic vascular remodeling [94]. In prolonged hypoxic conditions, an increased ratio of the microtubule-associated protein 1 light chain (LC3)-II to LC3-I has been observed in pulmonary arterial endothelial cells. Inhibition of autophagy by 3-methyladenine and beclin-1 knockdown led to decreased autophagy and increased *in vitro* angiogenesis [95].

Fibroblast, smooth muscle and endothelial cell proliferation cause thickening of the small pulmonary arteries, resulting in increased pulmonary vascular resistance. Increased proliferation of pulmonary arterial smooth muscle cells (PASMCs) and their resistance to apoptosis are key characteristics of PAH [96]. Induction of PAH by monocrotaline resulted to higher level of autophagy markers (i.e. LC3B-II, Atg5, p62); as well as decreased BMPR2 expression. Inhibition of autophagy by chloroquine prevented the development of PAH, right ventricular hypertrophy, and vascular remodeling. It has also suppressed the cellular proliferation, increased apoptosis and induced BMPR2 expression in PASMCs [97]. Thus, chloroquine exerted beneficial effects in experimental PAH.

ER stress and UPR are associated with the pathogenesis of PAH. IRE1, ATF6 and PERK have been associated to the PAH development. XBP1, CHOP, eIF2 α , BiP and Grp94 have been upregulated after four weeks of chronic hypoxia condition. Treatment with 4-phenylbutyric acid (4-PBA), a chemical chaperone and ER stress suppressor, remarkably reduced ER stress and attenuated the right ventricular hypertrophy and pulmonary artery remodeling in hypoxic mice [98, 99]. Moreover, the targeted inhibition of eIF2 α [100],

IRE1 α /XBP1 [101] and ATF6 [99] promoted apoptosis, inhibited proliferation, and reversed hypoxia-induced vascular remodeling.

Recent studies demonstrated that eIF2 α facilitates the proliferation of PASMCs and vascular remodeling through autophagy [102]. In addition, mTOR signaling enhanced the proliferation of PASMCs and induced PH via mTOR/eIF2 α pathway. The mTOR inhibitor rapamycin suppressed eIF2 α activation and attenuated vascular remodeling in hypoxia-induced PH [100].

ATF6 has been shown to accelerate the development of PAH through the upregulation of Nogo-B, a crucial protein for maintaining the tubular structure of ER. Induction of Nogo-B disrupts the ER-mitochondria unit, and suppresses the mitochondria-dependent apoptosis in PASMCs. The rescue of PASMCs from apoptosis during ER stress accelerates the development of PAH via proliferation [103].

Role of autophagy and UPR in tuberculosis.

Pulmonary tuberculosis (TB) is a chronic lung infection caused by the *Mycobacterium tuberculosis* (Mtb) [104, 105]. Autophagy has a crucial role in the pathogenesis of tuberculosis. Induction of autophagy is a potential mechanism to eliminate intracellular pathogens [106], and inhibition of autophagy may serve as a potential survival strategy of bacterial pathogens like Mtb. The fusion of autophagosome with lysosome could be hindered by the intervention of Mtb, and thus it prevents the maturation of autophagosome and subsequently the autolysosomal degradation in macrophages. On the other hand, non-Mtb-containing autophagosomes continue to mature into autolysosomes [107]. Stimulation of autophagy by rapamycin, IFN γ , or vitamin D upregulated the autophagic flux, which in turn potentiated the clearance of Mtb through autophagy [106, 108].

Vitamin D-mediated inhibition of Mtb growth is dependent not only on the induction of autophagy but also in autophagosomal maturation [108]. A ubiquitin-dependent mechanism has been demonstrated as a clearance mechanism of Mtb through autophagy [109, 110].

Autophagy exerts a dual role in tuberculosis. In addition to antibacterial activity, autophagy has been associated with anti-inflammatory activities. Mtb infection in Atg5 null increased the pulmonary inflammation [111]. Furthermore, autophagy in monocytes protected against Mtb infection. Autophagy augmentation enhanced antimicrobial activities against Mtb [112, 113]. Myeloid cell-specific deficiency of Atg5 significantly induced Mtb infection and reduced the survival rate of Mtb-infected mice [114]. Atg5 is protective against Mtb infection by preventing polymorphonuclear cell (PMN)-mediated immunopathology [114]. UPR has also been associated with the induction of apoptosis in macrophages and alveolar epithelial cells infected with Mtb. Apoptosis is a host defense mechanism which prevents the spread of mycobacterial infection to the surrounding tissue and is initiated by mycobacteria. Mtb H37Ra potentiates apoptosis in macrophages [115, 116] and secretes the highly immunogenic secretory antigenic target (ESAT-6), which perturbs the Ca²⁺ signaling. Disruption of Ca²⁺ homeostasis causes accumulation of ROS inside the cells, which in turn result in ER stress-induced apoptosis [117].

Mtb H37Rv has also been shown to suppress apoptosis. Phosphorylation of eIF2 α affects the survival of Mtb and suppresses the eIF2 α phosphorylation in a time-dependent manner [118]. Moreover, the modulation of the macrophage polarization is another mechanism employed by Mtb to circumvent the host immune system during tuberculous granulomas formation [119]. M1 macrophages induce inflammatory responses, promote granuloma formation and show resistance against intracellular parasites. The M2 macrophages mediate tissue repair and suppress the inflammatory process [119, 120]. M1 polarized macrophages demonstrate a higher ER stress to oppose Mtb. Infection with the Mtb H37Rv shows dominant expression of M2 macrophages, whereas the Mtb H37Ra infection resulted to increased levels of M1 macrophages [121].

Induction of apoptosis is more abundant in granulomas as compared to healthy tissue [122]. In addition, selective autophagy reduces the ER stress - induced apoptosis in Mtb-infected macrophages, and renders protection against Mtb. The BCL2 associated athanogene 2 (BAG2) induces reticulophagy, and suppresses ER stress. XBP1, transcriptionally inhibits BAG2 expression by binding to the *Bag2* promoter region. BAG2 activates autophagy through phosphorylation of BCL2 by MAPK during Mtb infection, and exerts anti-apoptotic effect. Indeed, BAG2 is a link between ER stress and autophagy in Mtb infection [123].

Autophagy and UPR in cystic fibrosis.

Cystic fibrosis (CF) is a lethal genetic disorder caused by mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, resulting in abnormal *CFTR* function. The most common mutation in *CFTR* gene is the deletion of phenyl alanine residue from the position-508 (F508del-*CFTR*) [124, 125]. The mutations in the *CFTR* gene impair protein synthesis; including gene transcription, protein translation, folding and trafficking [126]. Dysfunction of the *CFTR* protein causes severe disturbance to several key cellular mechanisms; including anion (chloride ion) transport, mucociliary-clearance, airway surface liquid (ASL) homeostasis [127], oxidative signaling [128], and autophagy.

Abnormal anion transport increases the mucin polymer cross-links and leads to thick mucus formation in the lungs [129]. This abnormal viscous mucus is an important characteristic of cystic fibrosis (CF) that blocks the airways. Those events result in chronic inflammation. Recurrent pulmonary infection occurs due to *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Burkholderia cepacia* [130].

Defective *CFTR* causes a maladaptive epithelial stress response associated with increased generation of reactive oxygen species (ROS), which in turn oxidizes and activates tissue transglutaminase (TG2) [131]. Activated TG2 targets several substrates, including Beclin 1 (BECN1). This is a major pro-autophagic protein which act as an activator of the phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3). Transamidation of BECN1 by TG2 causes the inhibition of autophagy, and accumulation of p62, which in turn regulate aggresome formation [132].

This disruption of the autophagic clearance causes the augmentation of inflammatory responses in *CFTR*-mutant mice [133]. Restoration of BECN1 by either beclin 1

overexpression or antioxidants, reverts the CF airway phenotype in vitro as well as in Scnn1b-transgenic and Cfr (F508del) homozygous mice [134]. Moreover, induction of autophagy by rapamycin or depletion of p62 decreased the bacterial survival and ameliorated the corresponding inflammatory responses [135].

CF is characterized by increased level of airway inflammation and chronic airway infection. Mutated CFTR in the pulmonary epithelial cells contributes to UPR activation [136]. Oxidative stress [137] and pathogens [138] may also accelerate CF through UPR induction. CFTR mutation can activate NF- κ B directly [139]; as well as through UPR-mediated NF- κ B activation [140]. Moreover, UPR induction is associated with the expansion of the ER Ca²⁺ store, which enhances inflammation [141].

Other studies have reported that ER stress suppresses the secretion of the neutrophil chemokines IL-8 and C-X-C motif chemokine ligand 1 (CXCL1); by inhibiting the activation of signal transducer and activator of transcription 3 (STAT3). Indeed, ER stress reduces neutrophil migration in the epithelial cells. Thus, ER stress alleviates the neutrophilic damage in CF airways, and reduces chemokine production [142].

Autophagy, UPR, acute lung injury and acute respiratory distress syndrome.

Acute lung injury (ALI) is an inflammatory lung disease, and it is characterized by the disruption of lung vascular endothelial and alveolar epithelial barriers [143, 144]. A severe form of acute lung injury is the acute respiratory distress syndrome (ARDS) [15, 145]. Different direct or indirect insults induce pulmonary inflammation, damage the alveolar-capillary membrane, and impair the function of the lungs [146, 147]. Those inflammatory processes lead to the accumulation of the protein-rich edema fluid in alveoli and interstitial space, reduction of alveolar fluid clearance, and impairment of the surfactant production and function [148]. Autophagy is involved in the pathogenesis of ALI/ ARDS.

Since the gas exchange capacity of the lung is significantly reduced during ARDS, mechanical ventilation (MV) becomes the most critical intervention in ARDS treatment [82]. It decreases the respiratory load of the patients by improving gas exchange. Even though MV supports ARDS patients, it has also been associated with aggravating lung injury [15, 149]. Interleukin (IL)-1 β is one of the most biologically active proinflammatory cytokines which induces ALI [150]. Mice that do not express Atg16L1 (*Atg16l1*^{fl/fl} *LysM*^{Cre}), developed ALI. On the other hand, induction of autophagy protected the mice from LPS plus mechanical ventilation-induced ALI. It has also improved the arterial oxygenation and lung permeability, as well as it suppressed IL-1 β production [151].

ALI may also occur due to high oxygen therapy (hyperoxia), a critical care setting to support tissue oxygenation. This is due to the enhanced ROS production in the lung capillary endothelial cells [152] and pulmonary epithelium [153]. Hyperoxia causes increased expression of autophagic markers; including autophagosome formation and pulmonary LC3B-II accumulation [154]. Suppression of LC3B by genetic interference promotes hyperoxia-induced cell death in pulmonary epithelial cells. Overexpression of LC3B showed

cellular protection after hyperoxia [154]. These results suggested the cytoprotective role of autophagic protein in hyperoxia-induced lung cell injury.

One of the most prominent pathophysiological characteristics of ALI is the lung microvascular endothelial barrier disruption. The endothelial cell-to-cell adherens junctions (AJs) are largely composed of vascular endothelial cadherin (VE-cadherin)/CDH5 and controls endothelial permeability [155]. Phosphorylation of CDH5 induces the dimer disassembly of CDH5 [156], which in turn increases endothelial permeability. The inflammatory tyrosine kinase Src [157] phosphorylates the tyrosine residues of CDH5 [158]. LC3 was associated with Src-selective autophagy [159].

Small GTPases mediate lung endothelial barrier function [160], including the RAB26. It was shown *in vivo* that RAB26 is downregulated in LPS-induced acute lung injury. On the contrary, LC3-II was associated with Src and promoted the degradation of the phosphorylated Src, when RAB26 was overexpressed. RAB26 induced autophagy by binding to ATG16L1 [161].

Autophagy exerted a protective role against cecal ligation and puncture (CLP)-induced acute lung injury. Elevated levels of LC3-II expression and accumulation of autophagosomes were detected in lung tissue of CLP-induced ALI [162]. Mice deficient in the Beclin 1 (*Becn1^{+/-}*) were more susceptible to CLP-induced ALI as compared to the wild-type mice. Moreover, *Becn1^{+/-}* mice showed a significant reduction of bacterial clearance from blood and vital organs after CLP treatment. These results showed that Beclin-1 is involved in the survival of the CLP-treated mice by enhancing bacterial clearance [162]. Another study showed that the expression of Atg7, Beclin-1, and LC3B-II were upregulated in CLP-induced ALI [163].

Upregulation of autophagy is the underlying mechanism of the protective effects of FK866 in ALI. This is a noncompetitive nicotinamide phosphoribosyl transferase inhibitor. FK866 reduced lung injury score, edema, vascular leakage, and inflammatory infiltration. The inhibition of autophagy by 3-MA (3-methyladenine) reduced the beneficial effect of FK866 towards ALI [163]. It has also been reported that 3-MA markedly reduced the lung vascular damage, tissue edema, levels of proinflammatory mediators, and lung neutrophil sequestration in an aerosolized bacterial LPS inhalation mouse model of ALI [164]. Another study has also reported deleterious effect of autophagy in endothelial barrier disruption due to thrombin-induced ALI. Silencing of Beclin-1 in human pulmonary arterial endothelial cells caused the reduction of several proinflammatory genes and NF- κ B activity. Moreover, knockdown of Beclin-1 reduced the thrombin-induced phosphorylation of RelA/p65, which is critical for the transcriptional activity of RelA/p65. Suppression of Beclin-1 prevented the disassembly of VE-cadherin, and thus protected against thrombin-induced EC barrier disruption [165].

UPR modulates vascular barrier function. It was reported that Kifunensine, a UPR suppressor, increases endothelial cell permeability by inducing the activation myosin light chain 2 (MLC2) and inhibiting the phosphorylation of cofilin [166]. Moreover, the heat shock protein 90 (Hsp90) inhibitors [167] and growth hormone releasing hormone (GHRH) antagonists [168] protect against the lipopolysaccharide (LPS)-induced ALI model. Hsp90

inhibitors have been shown to induce UPR and reduce the endothelial hyperpermeability [34, 169]. Those observations suggest the protective role of UPR in ALI/ARDS [37].

Conclusions

In our opinion, a carefully devised manipulation of autophagy in the context of UPR may deliver new therapeutic opportunities towards the inflammatory lung disease, including ALI/ARDS. Figure 1 concludes the information of our review.

Acknowledgments:

Dr. Barabutis' research is supported by 1) R&D, Research Competitiveness Subprogram (RCS), Louisiana Board of Regents through the Board of Regents Support Fund (LEQSF(2019-22)-RD-A-26) (PI: N.B) 2) Faculty Research Support Program from Dean's Office, College of Pharmacy, ULM (PI: N.B). 3) National Institute of General Medical Sciences of the National Institutes of Health (5 P20 GM103424-15, 3 P20 GM103424-15S1)

REFERENCES

- Mizushima N and Komatsu M, Autophagy: renovation of cells and tissues. *Cell*, 2011 147(4): p. 728–41. [PubMed: 22078875]
- Glick D, Barth S, and Macleod KF, Autophagy: cellular and molecular mechanisms. *J Pathol*, 2010 221(1): p. 3–12. [PubMed: 20225336]
- Yang Z and Klionsky DJ, Mammalian autophagy: core molecular machinery and signaling regulation. *Curr Opin Cell Biol*, 2010 22(2): p. 124–31. [PubMed: 20034776]
- Yorimitsu T and Klionsky DJ, Autophagy: molecular machinery for self-eating. *Cell Death Differ*, 2005 12 Suppl 2: p. 1542–52. [PubMed: 16247502]
- Parzych KR and Klionsky DJ, An overview of autophagy: morphology, mechanism, and regulation. *Antioxid Redox Signal*, 2014 20(3): p. 460–73. [PubMed: 23725295]
- Kohli L and Roth KA, Autophagy: cerebral home cooking. *Am J Pathol*, 2010 176(3): p. 1065–71. [PubMed: 20150434]
- Sheng R, et al., Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning. *Autophagy*, 2012 8(3): p. 310–25. [PubMed: 22361585]
- Kondo Y, et al., The role of autophagy in cancer development and response to therapy. *Nat Rev Cancer*, 2005 5(9): p. 726–34. [PubMed: 16148885]
- Qin L, et al., ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. *Autophagy*, 2010 6(2): p. 239–47. [PubMed: 20104019]
- Fagone P and Jackowski S, Membrane phospholipid synthesis and endoplasmic reticulum function. *J Lipid Res*, 2009 50 Suppl: p. S311–6. [PubMed: 18952570]
- Park SH and Blackstone C, Further assembly required: construction and dynamics of the endoplasmic reticulum network. *EMBO Rep*, 2010 11(7): p. 515–21. [PubMed: 20559323]
- Chen X, et al., Molecular characterization of the endoplasmic reticulum: insights from proteomic studies. *Proteomics*, 2010 10(22): p. 4040–52. [PubMed: 21080494]
- Hetz C, Chevet E, and Oakes SA, Proteostasis control by the unfolded protein response. *Nat Cell Biol*, 2015 17(7): p. 829–38. [PubMed: 26123108]
- Lin JH, Walter P, and Yen TS, Endoplasmic reticulum stress in disease pathogenesis. *Annu Rev Pathol*, 2008 3: p. 399–425. [PubMed: 18039139]
- Barabutis N, Unfolded Protein Response in Acute Respiratory Distress Syndrome. *Lung*, 2019 197(6): p. 827–828. [PubMed: 31605157]
- Glembotski CC, Rosarda JD, and Wiseman RL, Proteostasis and Beyond: ATF6 in Ischemic Disease. *Trends Mol Med*, 2019 25(6): p. 538–550. [PubMed: 31078432]
- Barabutis N, Unfolded Protein Response supports endothelial barrier function. *Biochimie*, 2019 165: p. 206–209. [PubMed: 31404589]

18. Bertolotti A, et al., Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol*, 2000 2(6): p. 326–32. [PubMed: 10854322]
19. Shen J, et al., ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. *Dev Cell*, 2002 3(1): p. 99–111. [PubMed: 12110171]
20. Harding HP, Zhang Y, and Ron D, Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature*, 1999 397(6716): p. 271–4. [PubMed: 9930704]
21. Wu J, et al., ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. *Dev Cell*, 2007 13(3): p. 351–64. [PubMed: 17765679]
22. Belmont PJ, et al., Regulation of microRNA expression in the heart by the ATF6 branch of the ER stress response. *J Mol Cell Cardiol*, 2012 52(5): p. 1176–82. [PubMed: 22326432]
23. Wang M and Kaufman RJ, Protein misfolding in the endoplasmic reticulum as a conduit to human disease. *Nature*, 2016 529(7586): p. 326–35. [PubMed: 26791723]
24. Bertolotti A, et al., Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient mice. *J Clin Invest*, 2001 107(5): p. 585–93. [PubMed: 11238559]
25. Martino MB, et al., The ER stress transducer IRE1beta is required for airway epithelial mucin production. *Mucosal Immunol*, 2013 6(3): p. 639–54. [PubMed: 23168839]
26. Kaufman RJ and Cao S, Inositol-requiring 1/X-box-binding protein 1 is a regulatory hub that links endoplasmic reticulum homeostasis with innate immunity and metabolism. *EMBO Mol Med*, 2010 2(6): p. 189–92. [PubMed: 20533428]
27. Lin JH, et al., IRE1 signaling affects cell fate during the unfolded protein response. *Science*, 2007 318(5852): p. 944–9. [PubMed: 17991856]
28. Korennykh AV, et al., The unfolded protein response signals through high-order assembly of Ire1. *Nature*, 2009 457(7230): p. 687–93. [PubMed: 19079236]
29. Karagoz GE, et al., An unfolded protein-induced conformational switch activates mammalian IRE1. *Elife*, 2017 6.
30. Lee AH, Iwakoshi NN, and Glimcher LH, XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. *Mol Cell Biol*, 2003 23(21): p. 7448–59. [PubMed: 14559994]
31. Calton M, et al., IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. *Nature*, 2002 415(6867): p. 92–6. [PubMed: 11780124]
32. Yamamoto K, et al., Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II. *J Biochem*, 2004 136(3): p. 343–50. [PubMed: 15598891]
33. Uddin M, et al., Effects of Heat Shock Protein 90 Inhibition In the Lungs. *Med Drug Discov*, 2020.
34. Kubra KT, et al., Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells. *Cell Signal*, 2020 67: p. 109500. [PubMed: 31837463]
35. Akhter MS, Uddin MA, and Barabutis N, Unfolded protein response regulates P53 expression in the pulmonary endothelium. *J Biochem Mol Toxicol*, 2019 33(10): p. e22380. [PubMed: 31339623]
36. Barabutis N, P53 In Lung Vascular Barrier Dysfunction. *Vascular Biology*, 2020.
37. Barabutis N, P53 in acute respiratory distress syndrome. *Cell Mol Life Sci*, 2020.
38. Ron D and Walter P, Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol*, 2007 8(7): p. 519–29. [PubMed: 17565364]
39. Digaleh H, Kiaei M, and Khodaghali F, Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. *Cell Mol Life Sci*, 2013 70(24): p. 4681–94. [PubMed: 23800989]
40. Yang Z, et al., Regulation of autophagy via PERK-eIF2alpha effectively relieve the radiation myelitis induced by iodine-125. *PLoS One*, 2013 8(11): p. e76819. [PubMed: 24223705]
41. B'Chir W, et al., The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. *Nucleic Acids Res*, 2013 41(16): p. 7683–99. [PubMed: 23804767]
42. Kouroku Y, et al., ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. *Cell Death Differ*, 2007 14(2): p. 230–9. [PubMed: 16794605]

43. Li Z, et al., Endoplasmic reticulum stress triggers Xanthoangelol-induced protective autophagy via activation of JNK/c-Jun Axis in hepatocellular carcinoma. *J Exp Clin Cancer Res*, 2019 38(1): p. 8. [PubMed: 30621754]
44. Haberzettl P and Hill BG, Oxidized lipids activate autophagy in a JNK-dependent manner by stimulating the endoplasmic reticulum stress response. *Redox Biol*, 2013 1: p. 56–64. [PubMed: 24024137]
45. Liu C, et al., IRE1 signaling pathway mediates protective autophagic response against manganese-induced neuronal apoptosis in vivo and in vitro. *Sci Total Environ*, 2020 712: p. 136480. [PubMed: 31931206]
46. Li DD, et al., The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. *Oncogene*, 2009 28(6): p. 886–98. [PubMed: 19060920]
47. Maejima Y, Isobe M, and Sadoshima J, Regulation of autophagy by Beclin 1 in the heart. *J Mol Cell Cardiol*, 2016 95: p. 19–25. [PubMed: 26546165]
48. Ogata M, et al., Autophagy is activated for cell survival after endoplasmic reticulum stress. *Mol Cell Biol*, 2006 26(24): p. 9220–31. [PubMed: 17030611]
49. Sharma M, et al., Japanese encephalitis virus activates autophagy through XBP1 and ATF6 ER stress sensors in neuronal cells. *J Gen Virol*, 2017 98(5): p. 1027–1039. [PubMed: 28535855]
50. Wang J, et al., Hepatitis C virus core protein activates autophagy through EIF2AK3 and ATF6 UPR pathway-mediated MAP1LC3B and ATG12 expression. *Autophagy*, 2014 10(5): p. 766–84. [PubMed: 24589849]
51. Yu Z, et al., Activation of the ATF6 branch of the unfolded protein response in neurons improves stroke outcome. *J Cereb Blood Flow Metab*, 2017 37(3): p. 1069–1079. [PubMed: 27217380]
52. Senior RM and Anthonisen NR, Chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med*, 1998 157(4 Pt 2): p. S139–47. [PubMed: 9563773]
53. Uddin MA and Barabutis N, P53 in the impaired lungs. *DNA Repair (Amst)*, 2020 95: p. 102952. [PubMed: 32846356]
54. Vestbo J, et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*, 2013 187(4): p. 347–65. [PubMed: 22878278]
55. Ryter SW, Lee SJ, and Choi AM, Autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. *Expert Rev Respir Med*, 2010 4(5): p. 573–84. [PubMed: 20923337]
56. Chen ZH, et al., Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. *PLoS One*, 2008 3(10): p. e3316. [PubMed: 18830406]
57. Kim HP, et al., Autophagic proteins regulate cigarette smoke-induced apoptosis: protective role of heme oxygenase-1. *Autophagy*, 2008 4(7): p. 887–95. [PubMed: 18769149]
58. Tran I, et al., Role of Cigarette Smoke-Induced Aggresome Formation in Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis. *Am J Respir Cell Mol Biol*, 2015 53(2): p. 159–73. [PubMed: 25490051]
59. Mizumura K, et al., Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. *J Clin Invest*, 2014 124(9): p. 3987–4003. [PubMed: 25083992]
60. Ito S, et al., PARK2-mediated mitophagy is involved in regulation of HBEC senescence in COPD pathogenesis. *Autophagy*, 2015 11(3): p. 547–59. [PubMed: 25714760]
61. Wang G, et al., Role of OSGIN1 in mediating smoking-induced autophagy in the human airway epithelium. *Autophagy*, 2017 13(7): p. 1205–1220. [PubMed: 28548877]
62. Liu M, et al., Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. *Gastroenterology*, 2014 146(4): p. 1084–96. [PubMed: 24417816]
63. Lam HC, et al., Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. *J Clin Invest*, 2013 123(12): p. 5212–30. [PubMed: 24200693]
64. He F, et al., Exposure to Ambient Particulate Matter Induced COPD in a Rat Model and a Description of the Underlying Mechanism. *Sci Rep*, 2017 7: p. 45666. [PubMed: 28361885]

65. Li X, et al., Taurine ameliorates particulate matter-induced emphysema by switching on mitochondrial NADH dehydrogenase genes. *Proc Natl Acad Sci U S A*, 2017 114(45): p. E9655–E9664. [PubMed: 29078374]
66. Monick MM, et al., Identification of an autophagy defect in smokers' alveolar macrophages. *J Immunol*, 2010 185(9): p. 5425–35. [PubMed: 20921532]
67. Tager AM and Luster AD, BLT1 and BLT2: the leukotriene B(4) receptors. *Prostaglandins Leukot Essent Fatty Acids*, 2003 69(2–3): p. 123–34. [PubMed: 12895595]
68. Marian E, et al., Up-regulated membrane and nuclear leukotriene B4 receptors in COPD. *Chest*, 2006 129(6): p. 1523–30. [PubMed: 16778270]
69. Dong R, et al., Cigarette smoke-induced lung inflammation in COPD mediated via LTB4/BLT1/SOCS1 pathway. *Int J Chron Obstruct Pulmon Dis*, 2016 11: p. 31–41. [PubMed: 26730186]
70. Yoshida T, et al., Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. *Nat Med*, 2010 16(7): p. 767–73. [PubMed: 20473305]
71. Delaunay-Moisan A and Appenzeller-Herzog C, The antioxidant machinery of the endoplasmic reticulum: Protection and signaling. *Free Radic Biol Med*, 2015 83: p. 341–51. [PubMed: 25744411]
72. Kenche H, et al., Cigarette smoking affects oxidative protein folding in endoplasmic reticulum by modifying protein disulfide isomerase. *FASEB J*, 2013 27(3): p. 965–77. [PubMed: 23169770]
73. Kelsen SG, et al., Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. *Am J Respir Cell Mol Biol*, 2008 38(5): p. 541–50. [PubMed: 18079489]
74. Geraghty P, Wallace A, and D'Armiento JM, Induction of the unfolded protein response by cigarette smoke is primarily an activating transcription factor 4-C/EBP homologous protein mediated process. *Int J Chron Obstruct Pulmon Dis*, 2011 6: p. 309–19. [PubMed: 21697995]
75. Min T, et al., Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. *J Mol Med (Berl)*, 2011 89(6): p. 577–93. [PubMed: 21318260]
76. Tagawa Y, et al., Induction of apoptosis by cigarette smoke via ROS-dependent endoplasmic reticulum stress and CCAAT/enhancer-binding protein-homologous protein (CHOP). *Free Radic Biol Med*, 2008 45(1): p. 50–9. [PubMed: 18394432]
77. Eltom S, et al., P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. *PLoS One*, 2011 6(9): p. e24097. [PubMed: 21915284]
78. Clauss M, et al., Lung endothelial monocyte-activating protein 2 is a mediator of cigarette smoke-induced emphysema in mice. *J Clin Invest*, 2011 121(6): p. 2470–9. [PubMed: 21576822]
79. Geraghty P, et al., Glutathione Peroxidase-1 Suppresses the Unfolded Protein Response upon Cigarette Smoke Exposure. *Mediators Inflamm*, 2016 2016: p. 9461289. [PubMed: 28070146]
80. Richens TR, et al., Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. *Am J Respir Crit Care Med*, 2009 179(11): p. 1011–21. [PubMed: 19264974]
81. Barabutis N, P53 in RhoA regulation. *Cytoskeleton (Hoboken)*, 2020 77(5–6): p. 197–201. [PubMed: 32105405]
82. Kubra KT, et al., P53 versus inflammation: an update. *Cell Cycle*, 2020 19(2): p. 160–162. [PubMed: 31880200]
83. Barabutis N, Regulation of lung endothelial permeability by NEK kinases. *IUBMB Life*, 2020 72(4): p. 801–804. [PubMed: 32045095]
84. Ito H, et al., Cigarette smoke induces endoplasmic reticulum stress and suppresses efferocytosis through the activation of RhoA. *Sci Rep*, 2020 10(1): p. 12620. [PubMed: 32724133]
85. Kaushik S and Cuervo AM, The coming of age of chaperone-mediated autophagy. *Nat Rev Mol Cell Biol*, 2018 19(6): p. 365–381. [PubMed: 29626215]
86. Hosaka Y, et al., Chaperone-Mediated Autophagy Suppresses Apoptosis via Regulation of the Unfolded Protein Response during Chronic Obstructive Pulmonary Disease Pathogenesis. *J Immunol*, 2020.
87. Galie N, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International

- Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*, 2009 30(20): p. 2493–537. [PubMed: 19713419]
88. Barman SA, et al., NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling. *Arterioscler Thromb Vasc Biol*, 2014 34(8): p. 1704–15. [PubMed: 24947524]
 89. Simonneau G, et al., Clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 2004 43(12 Suppl S): p. 5S–12S. [PubMed: 15194173]
 90. Simonneau G, et al., Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 2009 54(1 Suppl): p. S43–54. [PubMed: 19555858]
 91. Simonneau G, et al., Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 2013 62(25 Suppl): p. D34–41. [PubMed: 24355639]
 92. Machado RD, et al., Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol*, 2009 54(1 Suppl): p. S32–42. [PubMed: 19555857]
 93. Stenmark KR, Fagan KA, and Frid MG, Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. *Circ Res*, 2006 99(7): p. 675–91. [PubMed: 17008597]
 94. Lee SJ, et al., Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. *Am J Respir Crit Care Med*, 2011 183(5): p. 649–58. [PubMed: 20889906]
 95. Teng RJ, et al., Cross talk between NADPH oxidase and autophagy in pulmonary artery endothelial cells with intrauterine persistent pulmonary hypertension. *Am J Physiol Lung Cell Mol Physiol*, 2012 302(7): p. L651–63. [PubMed: 22245997]
 96. Morrell NW, et al., Cellular and molecular basis of pulmonary arterial hypertension. *J Am Coll Cardiol*, 2009 54(1 Suppl): p. S20–31. [PubMed: 19555855]
 97. Long L, et al., Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. *Circ Res*, 2013 112(8): p. 1159–70. [PubMed: 23446737]
 98. Koyama M, et al., Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. *Am J Physiol Heart Circ Physiol*, 2014 306(9): p. H1314–23. [PubMed: 24610918]
 99. Dromparis P, et al., Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. *Circulation*, 2013 127(1): p. 115–25. [PubMed: 23149668]
 100. Wang AP, et al., A Critical Role of the mTOR/eIF2alpha Pathway in Hypoxia-Induced Pulmonary Hypertension. *PLoS One*, 2015 10(6): p. e0130806. [PubMed: 26120832]
 101. Cao X, et al., The IRE1alpha-XBP1 pathway function in hypoxia-induced pulmonary vascular remodeling, is upregulated by quercetin, inhibits apoptosis and partially reverses the effect of quercetin in PASMCs. *Am J Transl Res*, 2019 11(2): p. 641–654. [PubMed: 30899368]
 102. Guo L, et al., eIF2alpha promotes vascular remodeling via autophagy in monocrotaline-induced pulmonary arterial hypertension rats. *Drug Des Devel Ther*, 2019 13: p. 2799–2809.
 103. Sutendra G, et al., The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. *Sci Transl Med*, 2011 3(88): p. 88ra55.
 104. Meena LS and Rajni, Survival mechanisms of pathogenic *Mycobacterium tuberculosis* H37Rv. *FEBS J*, 2010 277(11): p. 2416–27. [PubMed: 20553485]
 105. Ehrh S and Schnappinger D, Mycobacterial survival strategies in the phagosome: defence against host stresses. *Cell Microbiol*, 2009 11(8): p. 1170–8. [PubMed: 19438516]
 106. Gutierrez MG, et al., Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. *Cell*, 2004 119(6): p. 753–66. [PubMed: 15607973]
 107. Chandra P and Kumar D, Selective autophagy gets more selective: Uncoupling of autophagy flux and xenophagy flux in *Mycobacterium tuberculosis*-infected macrophages. *Autophagy*, 2016 12(3): p. 608–9. [PubMed: 27046255]
 108. Campbell GR and Spector SA, Vitamin D inhibits human immunodeficiency virus type 1 and *Mycobacterium tuberculosis* infection in macrophages through the induction of autophagy. *PLoS Pathog*, 2012 8(5): p. e1002689. [PubMed: 22589721]

109. Huang J and Brumell JH, Bacteria-autophagy interplay: a battle for survival. *Nat Rev Microbiol*, 2014 12(2): p. 101–14. [PubMed: 24384599]
110. Gomes LC and Dikic I, Autophagy in antimicrobial immunity. *Mol Cell*, 2014 54(2): p. 224–33. [PubMed: 24766886]
111. Castillo EF, et al., Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. *Proc Natl Acad Sci U S A*, 2012 109(46): p. E3168–76. [PubMed: 23093667]
112. Kim JK, et al., MIR144* inhibits antimicrobial responses against *Mycobacterium tuberculosis* in human monocytes and macrophages by targeting the autophagy protein DRAM2. *Autophagy*, 2017 13(2): p. 423–441. [PubMed: 27764573]
113. Tateosian NL, et al., IL17A augments autophagy in *Mycobacterium tuberculosis*-infected monocytes from patients with active tuberculosis in association with the severity of the disease. *Autophagy*, 2017 13(7): p. 1191–1204. [PubMed: 28581888]
114. Kimmey JM, et al., Unique role for ATG5 in neutrophil-mediated immunopathology during *M. tuberculosis* infection. *Nature*, 2015 528(7583): p. 565–9. [PubMed: 26649827]
115. Butler RE, et al., The balance of apoptotic and necrotic cell death in *Mycobacterium tuberculosis* infected macrophages is not dependent on bacterial virulence. *PLoS One*, 2012 7(10): p. e47573. [PubMed: 23118880]
116. Behar SM, et al., Apoptosis is an innate defense function of macrophages against *Mycobacterium tuberculosis*. *Mucosal Immunol*, 2011 4(3): p. 279–87. [PubMed: 21307848]
117. Choi HH, et al., Endoplasmic reticulum stress response is involved in *Mycobacterium tuberculosis* protein ESAT-6-mediated apoptosis. *FEBS Lett*, 2010 584(11): p. 2445–54. [PubMed: 20416295]
118. Lim YJ, et al., Endoplasmic reticulum stress pathway-mediated apoptosis in macrophages contributes to the survival of *Mycobacterium tuberculosis*. *PLoS One*, 2011 6(12): p. e28531. [PubMed: 22194844]
119. Huang Z, et al., *Mycobacterium tuberculosis*-Induced Polarization of Human Macrophage Orchestrates the Formation and Development of Tuberculous Granulomas In Vitro. *PLoS One*, 2015 10(6): p. e0129744. [PubMed: 26091535]
120. Liu YC, et al., Macrophage polarization in inflammatory diseases. *Int J Biol Sci*, 2014 10(5): p. 520–9. [PubMed: 24910531]
121. Lim YJ, et al., Roles of endoplasmic reticulum stress-mediated apoptosis in M1-polarized macrophages during mycobacterial infections. *Sci Rep*, 2016 6: p. 37211. [PubMed: 27845414]
122. Seimon TA, et al., Induction of ER stress in macrophages of tuberculosis granulomas. *PLoS One*, 2010 5(9): p. e12772. [PubMed: 20856677]
123. Liang S, et al., BAG2 ameliorates endoplasmic reticulum stress-induced cell apoptosis in *Mycobacterium tuberculosis*-infected macrophages through selective autophagy. *Autophagy*, 2020 16(8): p. 1453–1467. [PubMed: 31711362]
124. Cutting GR, Cystic fibrosis genetics: from molecular understanding to clinical application. *Nat Rev Genet*, 2015 16(1): p. 45–56. [PubMed: 25404111]
125. Bodas M and Vij N, Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease. *Front Pharmacol*, 2019 10: p. 20. [PubMed: 30774592]
126. Derichs N, Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. *Eur Respir Rev*, 2013 22(127): p. 58–65. [PubMed: 23457166]
127. Haq IJ, et al., Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. *Thorax*, 2016 71(3): p. 284–7. [PubMed: 26719229]
128. Ziady AG and Hansen J, Redox balance in cystic fibrosis. *Int J Biochem Cell Biol*, 2014 52: p. 113–23. [PubMed: 24657650]
129. Tang XX, et al., Acidic pH increases airway surface liquid viscosity in cystic fibrosis. *J Clin Invest*, 2016 126(3): p. 879–91. [PubMed: 26808501]
130. Stoltz DA, Meyerholz DK, and Welsh MJ, Origins of cystic fibrosis lung disease. *N Engl J Med*, 2015 372(4): p. 351–62. [PubMed: 25607428]
131. Maiuri L, et al., Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. *J Immunol*, 2008 180(11): p. 7697–705. [PubMed: 18490773]

132. Vilella VR, et al., Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect. *Front Pharmacol*, 2013 4: p. 1. [PubMed: 23346057]
133. Mayer ML, et al., Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. *J Immunol*, 2013 190(3): p. 1227–38. [PubMed: 23264659]
134. Luciani A, et al., Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. *Nat Cell Biol*, 2010 12(9): p. 863–75. [PubMed: 20711182]
135. Abdulrahman BA, et al., Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cfr DeltaF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery. *J Biol Chem*, 2013 288(3): p. 2049–58. [PubMed: 23148214]
136. Bartoszewski R, et al., Activation of the unfolded protein response by deltaF508 CFTR. *Am J Respir Cell Mol Biol*, 2008 39(4): p. 448–57. [PubMed: 18458236]
137. Chen AC, Burr L, and McGuckin MA, Oxidative and endoplasmic reticulum stress in respiratory disease. *Clin Transl Immunology*, 2018 7(6): p. e1019. [PubMed: 29928501]
138. van 't Wout EF, et al., Virulence Factors of *Pseudomonas aeruginosa* Induce Both the Unfolded Protein and Integrated Stress Responses in Airway Epithelial Cells. *PLoS Pathog*, 2015 11(6): p. e1004946. [PubMed: 26083346]
139. Wang H, et al., CFTR Controls the Activity of NF-kappaB by Enhancing the Degradation of TRADD. *Cell Physiol Biochem*, 2016 40(5): p. 1063–1078. [PubMed: 27960153]
140. Tam AB, et al., ER stress activates NF-kappaB by integrating functions of basal IKK activity, IRE1 and PERK. *PLoS One*, 2012 7(10): p. e45078. [PubMed: 23110043]
141. Ribeiro CM and Boucher RC, Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses. *Proc Am Thorac Soc*, 2010 7(6): p. 387–94. [PubMed: 21030518]
142. Tang AC, et al., Endoplasmic Reticulum Stress and Chemokine Production in Cystic Fibrosis Airway Cells: Regulation by STAT3 Modulation. *J Infect Dis*, 2017 215(2): p. 293–302. [PubMed: 27799352]
143. Johnson ER and Matthay MA, Acute lung injury: epidemiology, pathogenesis, and treatment. *J Aerosol Med Pulm Drug Deliv*, 2010 23(4): p. 243–52. [PubMed: 20073554]
144. Barabutis N, P53 in lung vascular barrier dysfunction. *Vasc Biol*, 2020 2(1): p. E1–E2. [PubMed: 32613156]
145. Barabutis N, Schally AV, and Siejka A, P53, GHRH, inflammation and cancer. *EBioMedicine*, 2018 37: p. 557–562. [PubMed: 30344124]
146. Ragaller M and Richter T, Acute lung injury and acute respiratory distress syndrome. *J Emerg Trauma Shock*, 2010 3(1): p. 43–51. [PubMed: 20165721]
147. Barabutis N, Heat shock protein 90 inhibition in the inflamed lungs. *Cell Stress Chaperones*, 2020 25(2): p. 195–197. [PubMed: 31950341]
148. Barabutis N, Verin A, and Catravas JD, Regulation of pulmonary endothelial barrier function by kinases. *Am J Physiol Lung Cell Mol Physiol*, 2016 311(5): p. L832–L845. [PubMed: 27663990]
149. Rittayamai N and Brochard L, Recent advances in mechanical ventilation in patients with acute respiratory distress syndrome. *Eur Respir Rev*, 2015 24(135): p. 132–40. [PubMed: 25726563]
150. Ganter MT, et al., Interleukin-1beta causes acute lung injury via alpha5 and alpha6 integrin-dependent mechanisms. *Circ Res*, 2008 102(7): p. 804–12. [PubMed: 18276918]
151. Nosaka N, et al., Autophagy Protects Against Developing Increased Lung Permeability and Hypoxemia by Down Regulating Inflammasome Activity and IL-1beta in LPS Plus Mechanical Ventilation-Induced Acute Lung Injury. *Front Immunol*, 2020 11: p. 207. [PubMed: 32117318]
152. Brueckl C, et al., Hyperoxia-induced reactive oxygen species formation in pulmonary capillary endothelial cells in situ. *Am J Respir Cell Mol Biol*, 2006 34(4): p. 453–63. [PubMed: 16357365]
153. Crapo JD, Morphologic changes in pulmonary oxygen toxicity. *Annu Rev Physiol*, 1986 48: p. 721–31. [PubMed: 3518622]

154. Tanaka A, et al., Hyperoxia-induced LC3B interacts with the Fas apoptotic pathway in epithelial cell death. *Am J Respir Cell Mol Biol*, 2012 46(4): p. 507–14. [PubMed: 22095627]
155. Dejana E, Orsenigo F, and Lampugnani MG, The role of adherens junctions and VE-cadherin in the control of vascular permeability. *J Cell Sci*, 2008 121(Pt 13): p. 2115–22. [PubMed: 18565824]
156. Cai J, et al., AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin. *Mediators Inflamm*, 2017 2017: p. 6893560. [PubMed: 28348461]
157. Barabutis N, et al., LPS induces pp60c-src-mediated tyrosine phosphorylation of Hsp90 in lung vascular endothelial cells and mouse lung. *Am J Physiol Lung Cell Mol Physiol*, 2013 304(12): p. L883–93. [PubMed: 23585225]
158. Wallez Y, et al., Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. *Oncogene*, 2007 26(7): p. 1067–77. [PubMed: 16909109]
159. Sandilands E, Schoenherr C, and Frame MC, p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy. *Cell Signal*, 2015 27(9): p. 1816–23. [PubMed: 26071201]
160. Barabutis N, P53 in RhoA regulation. *Cytoskeleton (Hoboken)*, 2020.
161. Dong W, et al., RAB26-dependent autophagy protects adherens junctional integrity in acute lung injury. *Autophagy*, 2018 14(10): p. 1677–1692. [PubMed: 29965781]
162. Lee S, et al., Carbon monoxide confers protection in sepsis by enhancing beclin 1-dependent autophagy and phagocytosis. *Antioxid Redox Signal*, 2014 20(3): p. 432–42. [PubMed: 23971531]
163. Zheng Q, et al., FK866 attenuates sepsis-induced acute lung injury through c-jun-N-terminal kinase (JNK)-dependent autophagy. *Life Sci*, 2020 250: p. 117551. [PubMed: 32179075]
164. Slavin SA, et al., Autophagy inhibitor 3-methyladenine protects against endothelial cell barrier dysfunction in acute lung injury. *Am J Physiol Lung Cell Mol Physiol*, 2018 314(3): p. L388–L396. [PubMed: 29074492]
165. Leonard A, et al., Critical role of autophagy regulator Beclin1 in endothelial cell inflammation and barrier disruption. *Cell Signal*, 2019 61: p. 120–129. [PubMed: 31054328]
166. Akhter MS, et al., Kifunensine compromises lung endothelial barrier function. *Microvasc Res*, 2020 132: p. 104051. [PubMed: 32730762]
167. Barabutis N, Uddin MA, and Catravas JD, Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation. *Cytokine*, 2019 113: p. 427–432. [PubMed: 30420201]
168. Uddin MA, et al., GHRH antagonists support lung endothelial barrier function. *Tissue Barriers*, 2019 7(4): p. 1669989. [PubMed: 31578921]
169. Uddin MA, et al., Effects of Heat Shock Protein 90 Inhibition In the Lungs. *Med Drug Discov*, 2020 6.

The unfolded protein response mediates autophagy and vice versa

Autophagy is involved in lung health and disease

The unfolded protein response maintains lung homeostasis

A novel therapeutic approach towards lung inflammatory disease may be developed based on autophagy manipulation

Endoplasmic reticulum stress triggers the unfolded protein response activation




Figure 1: Effects of autophagy and UPR on the pathogenesis of lung disease.

(A) Chronic obstructive pulmonary disease (COPD): Increased levels of autophagy damages the airway epithelium which leads to COPD. OSGIN1 induces the expression of autophagy genes, whereas NADH dehydrogenase suppresses autophagy. However, autophagy protects the alveolar macrophages, and reduces persistent inflammation in COPD. Moreover, reactive oxygen species (ROS) induces UPR, which in turn contributes in COPD pathogenesis. Chaperone-mediated autophagy (CMA) suppresses the production of ROS, and hence, protects against COPD. **(B) Pulmonary hypertension (PH):** Autophagy protects against hypoxia-induced pulmonary hypertension. On the other hand, it accelerates in pulmonary artery smooth muscle cells (PASMCs) proliferation, inducing PH. Suppression of autophagy by chloroquine reduces PASMCs proliferation, and prevents the development of PH and vascular remodeling. UPR is associated with the PH pathogenesis, and suppression of UPR by 4-phenylbutyric acid (4-PBA) attenuates the PH. **(C) Tuberculosis:** Rapamycin, IFN γ and vitamin D inhibit tuberculosis by inducing autophagy. BCL2-associated athanogene 2 (BAG2) induces reticulophagy in *Mycobacterium tuberculosis* (Mtb)-infected macrophages, and protects against tuberculosis. Moreover, UPR promotes apoptosis in macrophages and alveolar epithelial cells (AEC) to suppress tuberculosis. M1 polarized macrophages exhibit higher ER stress, thus resisting against Mtb infection. **(D) Cystic fibrosis:** UPR induces cystic fibrosis, whereas autophagy defends against this disease. Mutated CFTR enhances ROS production, which suppresses autophagy by activating transglutaminase 2 (TG2). Moreover, Oxidative stress, mutated CFTR and pathogens can cause cystic fibrosis through UPR activation. **(E) Acute lung injury/ Acute**

respiratory distress syndrome (ALI/ARDS): Both autophagy and UPR exert protection against ALI/ARDS. RAB26 suppresses LPS-induced ALI by inducing autophagy.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript